[1]焦小净 龚娟妮 邝土光 李积凤 张一笑 杨媛华.慢性阻塞性肺疾病急性加重期合并肺栓塞的患病率及临床特征分析[J].心血管病学进展,2024,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.021]
　JIAO Xiaojing,G ONG Juanni,K UANG Tuguang,et al.Incidence Rate and Clinical Characteristics of Pulmonary Embolism in Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Advances in Cardiovascular Diseases,2024,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.021]
点击复制

慢性阻塞性肺疾病急性加重期合并肺栓塞的患病率及临床特征分析()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年1期
页码:
84
栏目:
论著
出版日期:
2024-02-21

文章信息/Info

Title:
Incidence Rate and Clinical Characteristics of Pulmonary Embolism in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
作者:
焦小净 龚娟妮 邝土光 李积凤 张一笑 杨媛华
(首都医科大学附属北京朝阳医院呼吸与危重症医学科,北京 100020)
Author(s):
JIAO Xiaojing; G ONG Juanni; K UANG Tuguang; L I Jifeng; Z HANG Yixiao; Y ANG Yuanhua
(Department of Respiratory and Critical Care Medicine,Beijing Chaoyang Hospital Affiliated to Capital Medical University,Beijing 100020,China) , E-mailyyh1031@sina.com
关键词:
慢性阻塞性肺疾病急性加重期; 肺栓塞; 患病率; 临床特征
Keywords:
Acute exacerbation of chronic obstructive pulmonary disease; Pulmonary embolism; Incidence rate; Clinical features
DOI:
10.16806/j.cnki.issn.1004-3934.2024.01.021
摘要:
目的 评估慢性阻塞性肺疾病急性加重期（AECOPD）中肺栓塞（PE）的患病率，比较AECOPD合并PE的辅助检查及临床特征。方法 一项前瞻性、多中心研究纳入2016年12月--2023年1月在中国8所医院呼吸科住院的AECOPD患者，行CT肺动脉造影明确是否合并PE，收集并比较患者临床资料。结果 共纳入731例AECOPD患者，PE 患病率为15.3%。AECOPD合并PE者少痰（81.3% vs 42.0%，P＜0.01）、胸痛 (24.1% vs 9.2%）、咯血（11.6% vs 2.0%）、心悸（24.1% vs 0.5%）和晕厥（6.3% vs 0.2%）的发生率均明显高于单纯AECOPD者（P＜0.001）。 AECOPD合并PE组与单纯AECOPD组相比，PaO2为（76.27±26.22）mm Hg vs（76.01±25.67）mm Hg，PaCO2为（45.63±15.13）mm Hg vs（47.23±13.11）mm Hg，两组未见统计学差异（P＞0.05）。多因素回归分析显示D-二聚体（OR=52.61，95% CI 10.61～206.07）、N末端脑利钠肽前体（OR=3.01，95% CI 1.53～4.01）和少痰（OR=5.10，95% CI 2.953～8.635）是AECOPD发生PE的相关因素。影像学方面，112例PE患者中，双侧PE有69例（61.6%），多发PE有73例（65.2%）。血栓位置在主肺动脉干者有5例（4.5%），在左、右肺动脉干以上的有16例（14.3%），在叶支肺动脉及以上者有44例（39.3%），在段、亚段及以下肺动脉者的有13例（11.6%）。按照PE危险分层，高危PE有0例，中危PE有44例（39.3%），其中，中高危PE有15例（13.4%），中低危PE有29例（25.9%），低危PE有68例（60.7%）。结论 AECOPD合并PE的比例很高，出现胸痛、咯血、心悸 和晕厥需考虑到合并PE的可能性；D-二聚体、N末端脑利钠肽前体水平升高和少痰是AECOPD患者发生PE的重要相关因素，提示住院AECOPD合并PE患者可能无明显的咳痰症状，导致慢性阻塞性肺疾病急性加重的原因并非感染，可能是合并了PE。AECOPD患者合并PE的血栓位置符合一般PE的解剖学特点，危险分层以低危为主，高危少见。
Abstract:
Objective To evaluate the prevalence of pulmonary embolism(PE) in acute exacerbation of chronic obstructive pulmonary disease(AECOPD),and to compare the auxiliary examinations and clinical features of AECOPD combined with PE. Methods A prospective,multicenter study was conducted on AECOPD patients admitted to the respiratory department in 8 Chinese hospitals from December 2016 to January 2023. Computed tomographic pulmonary angiography was performed to determine whether PE was present ,and clinical data of patients were collected and compared. Results A total of 731 AECOPD patients were included,with a PE prevalence rate of 15.3%. The incidence of reduced sputum(81.3% vs 42.0%, P<0.01),chest pain (24.1% vs 9.2%),hemoptysis(11.6% vs 2.0%),palpitations(24.1% vs 0.5%) and syncope(6.3% vs 0.2%) in AECOPD patients with PE were significantly higher than those in AECOPD patients alone(P<0.001). Compared with the AECOPD group with PE alone,the PaO2 was (76.27±26.22 )mm Hg vs (76.01±25.67)mm Hg and PaCO2 was (45.63±15.13)mm Hg vs (47.23±13.11)mm Hg,and there was no statistically significant difference between the two groups( P>0.05). Multivariate regression analysis showed that D-dimer(OR=52.61, 95% CI 10.61～206.07), N-terminal pro-brain natriuretic peptide(OR=3.01, 95% CI 1.53～4.01),and reduced sputum( OR=5.10, 95% CI 2.953 ～8.635) were related factors for the occurrence of PE in AECOPD. In terms of imaging,among the 112 cases of PE,there were 69 cases(61 .6%) of bilateral PE and 73 cases(65.2%) of multiple PE. There were 5 cases(4.5%) with thrombus located on the main pulmonary artery trunk,16 cases(14.3%) above the left and right pulmonary artery trunk,44 cases(39.3%) above the lobar pulmonary artery,and 13 cases(11.6%) above the segmental,subsegmental and lower pulmonary arteries. According to the risk stratification of PE,there were 0 case of high-risk PE and 44 cases of medium risk PE(39.3%). Among them,there were 15 cases of medium high risk PE(13.4%), 29 cases of medium low risk PE(25.9%),and 68 cases of low risk PE(60.7%). Conclusion The proportion of AECOPD combined with PE is high,and the possibility of PE should be considered when chest pain,hemoptysis,palpitations and syncope occur. D -dimer,elevated N-terminal pro-brain natriuretic peptide,and reduced sputum are important factors related to the occurrence of PE in AECOPD. This suggests that hospitalized AECOPD patients with PE may not have obvious sputum symptoms,and the cause of chronic obstructive pulmonary disease with acute exacerbation is not infection,but may be combined with PE. The location of thrombosis in AECOPD patients with PE conforms to the anatomical characteristics of general PE,and the risk stratification is mainly low risk,with high risk being rare

参考文献/References:

[1].Murray CJ,Lopez AD. Mortality by cause for eight regions of the world:global burden of disease study[J]. Lancet,1997,349(9061):1269-1276.
[2].Cao YQ,Dong LX,Cao J. Pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Chin Med J(Engl),2018,131(14):1732-1737.
[3].Hoogendoorn M,Hoogenveen RT,Rutten-van M?lken MP,et al. Case fatality of COPD exacerbations:a meta-analysis and statistical modelling approach[J]. Eur Respir J,2011,37(3):508-515.
[4].Celli BR. Dissecting COPD exacerbations:time to rethink our definition[J]. Eur Respir J,2017,50(3):1701432.
[5].Ho TW,Tsai YJ,Ruan SY,et al. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations:a nationwide population-based study[J]. PLoS One,2014,9(12):e114866.
[6].Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease[J]. Nat Rev Drug Discov,2013,12(7):543-559.
[7].Sapey E,Stockley RA. COPD exacerbations. 2: aetiology[J]. Thorax,2006,61(3):250-258.
[8].Connors AF Jr,Dawson NV,Thomas C,et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease[J]. Am J Respir Crit Care Med,1996,154(4 Pt 1):959-967.
[9].Tillie-Leblond I,Marquette CH,Perez T,et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease:prevalence and risk factors[J]. Ann Intern Med,2006,144(6):390-396.
[10].Barnes PJ,Celli BR. Systemic manifestations and comorbidities of COPD[J]. Eur Respir J,2009,33(5):1165-1185.
[11].Lippmann M,Fein A. Pulmonary embolism in the patient with chronic obstructive pulmonary disease. A diagnostic dilemma[J]. Chest,1981,79(1):39-42.
[12].Moheimani F,Jackson DE. Venous thromboembolism:classification,risk factors diagnosis,and management[J]. ISRN Hematol,2011,2011:124610.
[13].Schneider C,Bothner U,Jick SS,et al. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases[J]. Eur J Epidemiol,2010,25(4):253-260.
[14].Rutschmann OT,Cornuz J,Poletti PA,et al. Should pulmonary embolism be suspected in
[15].exacerbation of chronic obstructive pulmonary disease?[J]. Thorax,2007,62(2):121-125.
[16].Aleva FE,Voets LWLM,Simons SO,et al. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD:a systematic review and meta-analysis[J]. Chest,2017,151(3):544-554.
[17].Hassen MF,Tilouche N,Jaoued O,et al. Incidence and impact of pulmonary embolism during severe COPD exacerbation[J]. Respir Care,2019,64(12):1531-1536.
[18].Xiong W,Du H,Xu M,et al. An authoritative algorithm most appropriate for the prediction
[19].of pulmonary embolism in patients with AECOPD[J]. Respir Res,2020,21(1):218.
[20].B?rvik T,Br?kkan SK,Enga K,et al. COPD and risk of venous thromboembolism and mortality in a general population[J]. Eur Respir J,2016,47(2):473-481.
[21].Crichlow A,Cuker A,Mills AM. Overuse of computed tomography pulmonary angiography in the evaluation of patients with suspected pulmonary embolism in the emergency department[J]. Acad Emerg Med,2012,19(11):1219-1226.
[22].Fedullo PF,Tapson VF. Clinical practice.The evaluation of suspected pulmonary embolism[J]. N Engl J Med,2003,349(13):1247-1256.
[23].Cochran ST,Bomyea K,Sayre JW. Trends in adverse events after Ⅳ administration of contrast media[J]. AJR Am J Roentgenol,2001 ,176(6):1385-1388.
[24].Stein PD,Terrin M,Hales CA,et al. Clinical,laboratory,roentgenographic,and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease[J]. Chest,1991,100(3):598-603.
[25].Kearon C,Akl EA,Ornelas J,et al. Antithrombotic therapy for VTE disease:CHEST Guideline and expert panel report[J]. Chest,2016,149(2):315-352.

相似文献/References:

[1]朱洪基,余建群,彭礼清.心电门控双源CTPA评价急性肺栓塞及其右心室功能[J].心血管病学进展,2019,(6):955.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.029]
　ZHU Hongji,YU Jianqun,PENG Liqing.Evaluation of Acute Pulmonary Embolism and Its Right Ventricular Function by ECG Gated Dual-source CTPA[J].Advances in Cardiovascular Diseases,2019,(1):955.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.029]
[2]张鹏 刘金波 王宏宇.静脉血栓栓塞症患者血浆生物标志物与肺栓塞的相关性研究[J].心血管病学进展,2022,(4):365.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.019]
　ZHANG Peng,LIU Jinbo,WANG Hongyu.Correlation Between Plasma Biomarkers and Pulmonary Embolism in?atients with Venous Thromboembolism[J].Advances in Cardiovascular Diseases,2022,(1):365.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.019]
[3]朱栋 何翔 李国平.基于Virchow三要素浅谈环境污染与肺栓塞疾病[J].心血管病学进展,2022,(11):984.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.005]
　ZHU Dong,HE Xiang,LI Guoping.Discussing Environmental Pollution and Pulmonary Embolic Disease Based on?irchows Triad[J].Advances in Cardiovascular Diseases,2022,(1):984.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.005]
[4]李梦依 刘英杰 齐灵垚 秦地茂.孟德尔随机化探讨三甲胺N-氧化物及其前体与静脉血栓栓塞的因果关系[J].心血管病学进展,2023,(8):764.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.020]
　Li Mengyi,Liu YingjieQi LingyaoQin Dimao.Mendelian Randomization Exploring the Causality of Trimethylamine N-oxide and Its Precursors with Venous Thromboembolism[J].Advances in Cardiovascular Diseases,2023,(1):764.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.020]
[5]王一佳 黄志华 高璐阳 赵智慧 赵青 罗勤 柳志红.人工智能在肺血管疾病诊治中的研究进展[J].心血管病学进展,2024,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.002]
　WANG Yijia,HUANG Zhihua,GAO Luyang,et al.Artificial Intelligence in Diagnosis and Treatment of Pulmonary Vascular Diseases[J].Advances in Cardiovascular Diseases,2024,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.002]
[6]丁兆慧 奚群英.双能量CT成像技术在肺血管疾病中的应用进展[J].心血管病学进展,2024,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.008]
　DING Zhaohui,XI Qunying.Dual-Energy CT Imaging in Pulmonary Vascular Diseases[J].Advances in Cardiovascular Diseases,2024,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.008]

更新日期/Last Update: 2024-03-06